As an early mover, RADLogics has accumulated the best know-how and the superior algorithm development tools. This is partly credited to its Co-founder and Chief Scientist Hayit Greenspan, who is a professor in the Department of Biomedical Engineering in Tel Aviv and an affiliated researcher at the Berkeley Institute of Computer Science in California, USA. She is the contributor to product development, one of the pioneers first engaged in applying deep learning to medical imaging applications, and a highly acclaimed researcher in the field. In addition, the company has partnered with some major OEM distribution partners – including Nuance and others in key markets – with global reach, that enable rapid deployment of the company's AI-Powered solutions. With over a decade of experience, RADLogics has deployed its solution globally and processed millions of CT and X-ray scans from clinical sites in the U.S., Europe, Russia, China and India.
"As pioneers in AI technology and machine learning, this is an exciting partnership between RADLogics and PVmed that will extend our collective reach and capabilities to enhance medical imaging, clinical teams and radiologists across Asia," said Moshe Becker, CEO and Co-Founder of RADLogics. "In particular, much of our early work and studies around the potential for AI-Powered solutions to support COVID-19 detection and quantification started in China, so it is only fitting that our collaboration will help alleviate the burden on health systems recovering from the pandemic throughout the region by expanding access to new tools that will augment caregivers and clinicians."
RADLogics' AI-Powered software includes algorithms that not only detect abnormalities on chest CTs and X-rays, but also provide automatic triage alerts to the radiologist to help ensure potential findings are reviewed in a timely matter. In addition, the AI-Powered devices provide quantitative analysis of the CT and X-ray images for patients with suspected COVID-19 disease including a score that can help monitor findings over time. In response to the COVID-19 pandemic, RADLogics has dedicated the company's resources to modify, adapt, and deploy its algorithms to detect lung abnormalities that are compatible with COVID-19 in appropriate clinical settings.